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GSK3 has diverse functions, including an important role in brain pathology. In this paper, we address the primary functions
of GSK3 in development and neuroplasticity, which appear to be interrelated and to mediate age-associated neurological
diseases. Speciﬁcally, GSK3 plays a pivotal role in controlling neuronal progenitor proliferation and establishment of neuronal
polarity during development, and the upstream and downstream signals modulating neuronal GSK3 function aﬀect cytoskeletal
reorganization and neuroplasticity throughout the lifespan. Modulation of GSK3 in brain areas subserving cognitive function has
become a major focus for treating neuropsychiatric and neurodegenerative diseases. As a crucial node that mediates a variety of
neuronal processes, GSK3 is proposed to be a therapeutic target for restoration of synaptic functioning and cognition, particularly
in Alzheimer’s disease.
1.GSK3 SignalingPathway
Manydiseasesofthecentralnervoussystemarecharacterized
by changes in the structural organization of neuronal
networks, developmental abnormalities, or dysregulation
of signaling pathways, leading to altered brain plasticity
and, ultimately, neurodegeneration. The proline-directed
serine/threonine kinase, glycogen synthase kinase 3 (GSK3),
has been suspected to be a contributing factor in psychiatric
illness and age-associated neurodegenerative diseases for
some time [1]. The involvement of GSK3 misregulation
in a variety of brain abnormalities strongly supports its
pivotal role as a metabolic crossroads for controlling basic
mechanisms of neuronal function from brain bioenerget-
ics to establishment of neuronal circuits, modulation of
neuronal polarity, migration, neuronal proliferation, and
survival [2]. In particular, the role of GSK3 in phosphory-
lation of cytoskeletal proteins impacts neuronal plasticity,
as cytoskeletal constituents are involved in the development
and maintenance of neurites, and changes in the rate
of stabilization/destabilization of microtubules (MT) could
inﬂuence major cellular compartments of neurons, such as
dendrites, spines, axons, and synapses.
The metabolic function of GSK3 was ﬁrst described
in glycogen metabolism, as GSK3 phosphorylates glycogen
synthase in response to insulin [3]. Since then, research has
identiﬁed a multitude of substrates and functions for this
enzyme. GSK3 exists in cells as two distinct gene products, α
and β, which exhibit high homology in the catalytic domain
but diﬀer in the N- and C-terminal sequences [4]. GSK3 is
ubiquitousthroughouttheanimalkingdom[5]andiswidely
expressed in all tissues with particularly abundant levels in
the brain [4], where the neuron-speciﬁc isoform GSK3β2i s
found [6].
GSK3 is unique because it is constitutively active, and
upstream signals downregulate its activity by phosphory-
lation at speciﬁc residues. The most important phospho-
residues are serine (Ser) 21 for GSK3α and Ser9 for
GSK3β, which inhibit its kinase activity [2, 7–10], while
phosphorylation on tyrosine (Tyr) residues (Tyr 216/279
for GSK3β and GSK3α, resp.), is required for its activation
[11–13]. The latter kind of phosphorylation is mediated by2 International Journal of Alzheimer’s Disease
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Figure 1: Modulation of GSK3 activity by phosphorylation. Protein phosphatases 1 and 2A activate GSK3 by removing Ser9/21
phosphorylation. It has also been reported that phosphorylation in tyrosine residues by members of the receptor tyrosine kinase family
of cell surface receptors (RTKs) or by autophosphorylation may activate GSK3. On the other hand, signaling networks activate several
protein kinases, which may bring about phosphorylation of diﬀerent residues and inhibition of GSK3.
diverse tyrosine kinases [14] or by autophosphorylation [15]
(Figure 1).
Multiple kinases can phosphorylate Ser21/9, including
Akt, protein kinases A and C, p70S6K, and p90RSK [16].
In contrast, protein phosphatases 1 (PP1) and 2A (PP2A)
dephosphorylate the inhibitory site of GSK3, resulting in
activation of the enzyme. In addition to the inhibitory
phosphorylation of GSK3β described above, an additional
inhibitorysiteatSer389hasbeendetectedinthebrain,which
is phosphorylated by p38 mitogen-activated protein kinase
(MAPK) [17].
In addition to its phosphorylation state, GSK3 activity
may be regulated by proteolysis through disruption of the
axin-β-catenin complex [18] or N-terminal cleavage by the
calcium-dependent protease calpain [19]. GSK3 activity also
depends on its cellular localization. Although GSK3 is pre-
dominantly located in the cytosol, it is also present in nuclei
and mitochondria, where it is highly activated compared
with the cytosolic pool [20]. Nuclear GSK3 regulates the
expression of diverse genes via various transcription factors,
such as Ap-1, β-catenin, c-myc, and p53 [16]. Subtle control
of GSK3-mediated activation and inhibition is required
to ensure a proper balance among cell morphoregulation,
proliferation, and growth. Thus, prolonged inhibition of
GSK3 is associated with hypertrophic cell growth [21], while
sustained activation is associated with neurodegeneration
[22]. Unlike other kinases, the majority of GSK3 substrates
require a “priming” phosphorylation on Ser/Thr residues,
which is catalyzed by a protein kinase other than GSK3
[2, 10, 16].
2. Implicationsof GSK3ActivityinBrain
In adulthood, both GSK3α and GSK3β are expressed in mice
adult brain and are particularly enriched in hippocampus,
neocortex, and cerebellum [23]. In rodent adult hippocam-
pus GSK3β is more abundant than GSK3α [24], and in aged
hippocampus GSK3β is elevated, but not GSK3α [25]. Two
splice variants of the GSK3β gene are found in neurons
from mouse, rat, and human: GSK3β1a n dG S K 3 β2, the
latter being highly expressed during brain development
and speciﬁc to neurons [6, 26–28]. The two isoforms
are diﬀerentially involved in phosphorylation of diﬀerent
substrates [29] and establishment of neuronal polarity and
axon guidance [2, 30–32].
The importance of GSK3 in brain function has been
established by several studies in transgenic mice, which
have shown diﬀerent neurological defects depending of the
speciﬁc GSK3 isoform involved. While deletion of GSK3β is
lethal, heterozygote mice survive and present increased anx-
iety and reduced exploration [33–35]. Conversely, knockout
GSK3αmicearequitenormal[36],althoughneuron-speciﬁc
knockout of GSK3α results in reduced anxiety, locomotor
activity,andaggression[37].Overexpressionofaninhibitory
phosphorylation-resistant form of GSK3 results in increased
locomotor activity and has been proposed as a model
of manic illness [38]. Moreover, overexpressed GSK3β in
dentate gyrus results in tau-dependent neurodegeneration of
this region [39]. In the brain, GSK3 regulates developmental
processes, including neurogenesis, migration, axon growth
and guidance, and synaptic plasticity [40], and its activity
is controlled through several signaling pathways activated by
growth factors, wingless (Wnt) proteins, G-protein-coupled
receptors (GPCR), β-arrestin, among other proteins [41].
Abnormal activation of GSK3 has been associated
with several neurological and psychiatric disorders that
share developmental abnormalities and altered neurocir-
cuitry maintenance, such as schizophrenia, bipolar disorder,
autism, and Alzheimer’s disease (AD) [42–46]. GSK3 is
indeed a common therapeutic target for neuropsychiatric
drugs [41, 47].
3. SignalingPathways Involvedin
GSK3ActivityinBrain
GSK3 is a downstream component of several signaling
pathways in the brain. One of the most studied is the
phosphoinositide-3-OH kinase (PI3K)/Akt pathway, which
playsacrucialroleindiﬀerentiation and survivalof neuronal
and glial cells [48]. Growth signals, Ras proteins [49],International Journal of Alzheimer’s Disease 3
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Figure 2: Canonical Wnt signaling and GSK3 regulation. Wnt activation trough Frizzled receptor (FzR) induces destabilization of the
protein complex composed of axin, adenomatous polyposis coli (APC) protein, β-catenin, casein kinase (Ck1), and GSK3, which results in
GSK3 inhibition leading to the induction of β-catenin/TCF target gene expression. When Wnt signalling is oﬀ the GSK3/axin complex is not
inhibited and β-catenin phosphorylated and is degraded by the proteasome machinery.
or diminished phosphatase and tensin homolog (PTEN)
all activate the catalytic subunit of PI3K, which phos-
phorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to
phosphatidylinositol-3,4,5-trisphosphate (PIP3) and acti-
vates phosphoinositide-dependent protein kinase-1 (PDK-
1). Meanwhile, signaling proteins with pleckstrin homology
(PH) domains accumulate at sites of PI3K activation on the
inner surface of the plasma membrane through interactions
between their PH domains and the phospholipid products of
PI3K. Next, the serine-threonine kinase Akt/protein kinase B
is recruited and phosphorylated by PDK-1, which stimulates
thecatalyticactivityofAkt,inturnphosphorylating GSK3to
downregulate its activity.
The canonical Wnt pathway is also classically involved
in negative regulation of GSK3. Although the role of Wnt
proteins in mature neurons remains largely unexplored,
recent data indicate that Wnts are important mediators of
neuronal function, neuronal morphology, neurogenesis, and
synaptic plasticity [50–52]. Interestingly, Wnt signaling has
also been implicated in neurological disorders associated
with developmental abnormalities, such as schizophrenia
[53], as well as in chronic neurodegenerative diseases, such
as AD [54]. Extracellular secreted Wnt proteins activate
Frizzled receptor and/or the low-density lipoprotein-related
protein 5 and 6 (LRP5/6) receptors, leading to the char-
acteristic activation of the Wnt canonical pathway [55].
Due to Frizzled activation, the Dishevelled mammalian
homolog Dvl1 is recruited, inducing destabilization of the
protein complex composed of axin, adenomatous polyposis
coli (APC) protein, β-catenin, and GSK3β, which results
in GSK3β inactivation [56]. Inhibition of GSK3β favors
an increase in unphosphorylated β-catenin levels, allowing
interaction with members of the lymphoid enhancer factor/
T-cell factor (LEF/TCF) family of transcription factors and,
as a consequence, promoting the expression of cell survival
genes [57]. Although the molecular mechanism of GSK3
inhibition is not completely understood, Wnt signaling has
recently been reported to trigger the sequestration of GSK3
from the cytosol to multivesicular organelles, preventing its
interaction with cytoplasmic substrates [58]( Figure 2).
The outcome is diﬀerent in the absence of the Wnt
stimulation, which may occur due to lack of Wnt ligands
or the presence of Wnt negative modulators, such as the
extracellular protein Dickkopf-1 (DKK1), which regulates
the canonical Wnt signaling, or the secreted Frizzled-related
protein, which modulates both canonical and noncanonical
Wnt signaling [59]. Under these circumstances, GSK3β
is activated and able to phosphorylate its target proteins.
Several regulators also target β-catenin/GSK3β signaling.
For example, the product of disrupted in schizophrenia
1 (DISC1) gene inhibits GSK3β activity through a direct
physical interaction, causing stabilization of β-catenins.4 International Journal of Alzheimer’s Disease
DISC1 loss-of-function in the dentate gyrus has been shown
to result in reduced neural progenitor proliferation and to
elicit hyperactive and depressive behaviors in mice [60], sug-
gesting the involvement of GSK3β overactivation in mental
illnesses, such as depression and schizophrenia. Moreover,
DISC1 function seems to be essential for neural progenitor
proliferation in embryonic brains and in the dentate gyrus
of adult brains through its ability to control GSK3 activity
and to maintain β-catenin levels, which ultimately impacts
the neural circuitry [60].
GSK3β is also a downstream mediator of dopamine
signaling via the dopamine D2 receptor/β-arrestin 2/PP2A
complex. In this signaling pathway, Akt activates neuregulin-
1 signaling leading to inhibition of GSK3β activity [61].
Interestingly, neuregulin-1 has been also implicated as
schizophrenia risk factor [62].
InadditiontothedescribedroleofGSK3βinneurodevel-
opment, it has been recently found the potentiation of Notch
signalling by PI3K through GSK3β inhibition [63]. The
Notch pathway has been implicated in controlling cell fate,
diﬀerentiation, development as well as synaptic plasticity,
learning and memory [64].
4. GSK3: A Switchfor Cytoskeletal
Reorganization andSynapticPlasticity
Changes in neuronal morphology and plasticity are aﬀected
by GSK3-induced phosphorylation of proteins involved in
the modulation of MT and neuroﬁlament stabilization,
which aﬀect the cytoskeleton [65]. Among these proteins are
tau,microtubule-associatedprotein2(MAP2),microtubule-
associated protein 1B (MAP1B), collapsin response mediator
protein2,APC,axin,neuroﬁlaments,kinesinlightchain,and
cytoplasmic linker protein [9, 16, 30, 31, 40, 53, 66–70].
The induction of polarity during neuronal development
is essential for the establishment of circuits that support
complex functioning [71, 72]. Subcellular location of the
inactive form of GSK3β varies depending on the state
of neuronal polarization, as it moves from nonpolarized
neurites to the neurite tip that will form the axon at the
beginning of the diﬀerentiation process. Local inactivation
of GSK3 is important to allow axonal growth concurrent
with its activation in dendrites [73–76]. These mechanisms
support the establishment of neuronal polarity, which is
dependent on the stability and dynamism of the MT in each
neuronal compartment [40, 53]. The relationship between
GSK3β and the microtubule stabilizing protein complex
APC-mPar3, which are both present at the tip of the actively
growing nascent axon, is important for the establishment of
neuronalpolarity.Shiandcolleagues[74]havedemonstrated
that spatially regulated GSK3 activity in hippocampal neu-
rons during development leads to axonal generation [74].
The inactivation of GSK3 at the nascent axon is required
for mPar3 targeting through APC and kinesin-mediated
transport at the plus end of the axonal MT [74].
Two further studies showed that GSK3β inhibition in
hippocampal neurons induces formation of multiple axons
[75, 76]. However, the role of GSK3 in neurodevelopment
remains only partially understood due to contradictory data;
other studies have found that GSK3 inhibition induces
axonal spreading, reduces axonal elongation, and increases
growth cone size, but it does not induce the formation of
multiple axons [66, 68, 77–79].
One mechanism related to both synaptic reorganization
and MT dynamics is Wnt signaling [80–82], which directs
thegrowingaxontowardsthesynapticterminal.Thisprocess
involves the reduction of axonal growth speed and the
extension of axonal distal portions at the growth cone [83]
until arborization forms functional synaptic endings where
thepresynapticapparatuscanbeassembled.Transmembrane
proteins, such as neuroligin/neurexin and cadherins, are also
involved in this process and serve to regulate assembly on
both sides of the synapse [52, 84]. Wnt proteins have a
fundamental role in synapse formation, acting as retrograde
signals that regulate assembly of the presynaptic apparatus
[84]. Speciﬁcally, Wnt7a has a dual function in synaptic
diﬀerentiation, promoting axon remodeling and increasing
incorporation of synaptic proteins [66, 84]. These eﬀects
are linked to changes in the reorganization and dynamics
(stabilization-destabilization) of MT, which are achieved
through the canonical Wnt signaling, independent of the
transcription pathway, in which GSK3β activity is inhibited,
and, consequently, the phosphorylation state of the axonal
MAP1B is reduced [84–86]. The addition of Wnt7a to
neuronal cultures reduces MAP1B phosphorylation and
induces MT depolymerization from growing areas of the
axon, promoting axonal growth cone enlargement and
axonal spread [51, 66, 87]. The classical inhibition of GSK3β
by lithium chloride (LiCl) reproduces the eﬀects of Wnt7a,
inducing axonal arborization and widening and enlargement
of the growth cone through remodeling of axonal MT during
postnatal development of cerebellar cells [52, 87, 88]. On
the other hand, it has been shown that Wnt7a increases the
level of Synapsin I (SynI), which is known to be involved
in synapse formation, as well as in the maturation and
transport of synaptic vesicles in areas of growth [87, 89, 90].
Accumulation of SynI promotes both axonal remodeling and
synaptogenesis during cerebellar development [87] and is
mimicked by LiCl treatment [66, 88, 91].
GSK3 is also present in mature synapses [92], where its
activity, along with that of cyclin-dependent kinase (Cdk5),
participates in the recovery of synaptic vesicles during high
neuronal activity. During this process, Cdk5 phosphorylates
the GTPase dynamin I, and then GSK3β phosphorylates
the same dynamin I [93]. Both phosphorylation events are
necessary and suﬃcient to trigger and maintain activity-
dependent bulk endocytosis of vesicles [94].
As a result of controlling diﬀerent morphofunctional
aspects of adult brain plasticity, GSK3 also plays a role
in long-term potentiation (LTP) [95, 96] and long-term
depression (LTD). LTP might be considered the electro-
physiological correlate of learning based on its synaptic
mechanisms and long-lasting experience-dependent cortical
circuits [97–99]. On the other hand, LTD has been suggested
as a mechanism to enhance the signal-to-noise ratio of
sensory input from stored memories [97]. Some studies have
shownthatGSK3β inhibitionupregulatesandmaintainsLTP
[24, 50, 91, 100–102], while GSK3β remains active duringInternational Journal of Alzheimer’s Disease 5
LTD [101]. In rat hippocampus, GSK3β overactivation
has been shown to impede LTP and aﬀect synapses by
decreasing both synaptic transmission and release of the
presynaptic neurotransmitter glutamate [91]. This is reg-
ulated by proteins associated with synaptic vesicles, such
as SynI [103–108], which is considered to be a synaptic
plasticity marker [109, 110]. GSK3β activation inhibits SynI
expression after LTP induction and simultaneously disrupts
SynIclustering,whichresultsfromelevatedneuronalactivity
[91].
An other evidence that underscores the importance
of GSK3 in brain plasticity is derived from experiments
conducted in rat hippocampus by G´ omez de Barreda and
colleagues. The authors found that inhibitory phospho-
rylation of GSK3 at Ser9 increased at the time of LTP
induction was maintained for up to one hour in vivo and
was signiﬁcantly higher in the hippocampal CA1 and dentate
gyrus subregions, which are involved in learning and mem-
ory acquisition [39]. Transgenic mice overexpressing GSK3
showed reduced LTP induction [100]. These data conﬁrm
the signiﬁcant participation of GSK3 in LTP regulation by
enabling LTP when its catalytic activity is inhibited and
preventing LTP when it is overactive. The inhibition of the
two main signaling pathways (insulin/PI3K and Wnt) which
induced an activation of GSK3 also prevents the induction of
LTP [50, 64, 111–113].
GSK3 has been shown to induce LTD through presynap-
tic and postsynaptic mechanisms. In the presynaptic neuron,
upregulation of GSK3 decreases the expression of SynI [91],
which has been linked to a decrease in glutamate release
[103]. In the postsynaptic neuron, GSK3 activation causes
changes in levels of synapse-associated proteins [114, 115],
evident as downregulation of the NR2A/B subunits of
NMDA receptors and of the scaﬀolding protein postsynaptic
density 93 (PSD93) [24, 91]. In addition, a transient activa-
tion of NMDA receptors and endocytosis of AMPA receptors
occurs [116, 117], leading to the loss of GSK3 inhibition due
to insuﬃcient Ca2+ entry. This GSK3 inhibition is mediated
by NMDA-PI3K-Akt signaling [112, 118]. Over-activity of
GSK3 may also induce MT destabilization in dendrites and
axons [80, 86, 119]( Figure 3).
Overexpression of GSK3β in mice prevents the induction
of LTP [100] and causes spatial memory deﬁcits [120]. These
data suggest that GSK3β plays an essential role in memory
formation through three general processes: (i) phosphoryla-
tion of substrates involved in synaptic remodeling, necessary
for the establishment of new connections, (ii) turnover
of cytoskeletal proteins such as MAPs, actin, and tubulin,
promoting disassembly, a condition required for a proper
synaptic reorganization, and (iii) involvement in the two
major forms of synaptic plasticity in the brain, LTP, and
LTD [121].
In summary, the functional consequence of GSK3 over-
activation in mature neurons is inhibition of LTP and
induction of LTD [101, 121], which could be linked to
deﬁciencies of memory and learning characteristic of some
neurological diseases, such as AD.
5. GSK3 andAlzheimer’s Disease
ADrepresentsaseriousepidemiologicalproblem,asitisnow
recognized as the most common age-related neurodegenera-
tive disease. Evidence supports a role for GSK3 in producing
some of the characteristic hallmarks of AD: extracellular
accumulation of amyloid-β protein (Aβ) and intraneuronal
neuroﬁbrillary tangles (NFTs) composed of hyperphospho-
rylated forms of tau and inﬂammatory markers [122]. All
of these eﬀects contribute to synaptic and neuronal loss and
memory decline [123, 124].
It has been proposed that overactivation of GSK3 in
AD leads to inhibition of LTP and may partially explain
the learning and memory deﬁcits present early in this
neurodegenerative disorder. On the other hand, changes in
GSK3 activity may be a molecular link between the two
main histopathological markers: Aβ overproduction and tau
hyperphosphorylation [39, 46, 125, 126].
TheNFTsthataccumulateinADareanomalousﬁlamen-
tous structures composed mainly of abnormal, hyperphos-
phorylated forms of tau protein [127]. Hence, numerous
studies have focused on identiﬁcation of the protein kinases
and phosphatases regulating tau phosphorylation in vivo.
GSK3β was recognized as a primary kinase involved in
tau phosphorylation, as was apparent from the ﬁrst studies
that termed it tau protein kinase-I [128]. Thus, GSK3β
has been identiﬁed as one of the major enzymes mediating
tau hyperphosphorylation at the residues implicated in
neurodegenerative tauopathies, including AD [129].
Normally, tau protein contains a total of 85 phosphory-
lable sites: 45 Ser, 35 Thr, and 5 Tyr. Of these, 40 have been
identiﬁed as phosphorylated in insoluble tau in AD brain: 28
Ser, 10 Thr, and 2 Tyr, and GSK3β can phosphorylate 23 of
these sites [130]. Although GSK3β commonly needs priming
phosphorylation of tau, three sites were recently found that
can be phosphorylated by GSK3β alone, without priming:
Ser396, Ser400, and Ser404 [131]. Furthermore, initial
phosphorylation of the Ser214 by cAMP-dependent protein
kinase was shown to lead to the rapid modiﬁcation of four
additional sites by GSK3β [131]. Studies in transgenic mouse
models have shown that overexpression of GSK3β results
in neurodegeneration and have unequivocally demonstrated
that GSK3β phosphorylates tau in AD-related phospho-
epitopes in vivo [93, 132, 133]. Moreover, co-overexpression
of tau and GSK3β synergistically increased tau phosphoryla-
tion and induced neuronal death in a transgenic model in
Drosophila [134] while GSK3 inhibition reduces the phos-
phorylation and aggregation of tau [135, 136]. Similarly, tau
hyperphosphorylation and neurodegeneration after GSK3β
overexpression are exacerbated by co-overexpression of tau
with mutations characteristic of frontotemporal dementia
with parkinsonism, associated with chromosome 17 (FDTP-
17).Thisstudyalsoshowedthattauopathyprogressioncould
be prevented by administration of a GSK3β inhibitor at the
ﬁrst signs of pathology [133]. Tau knockout mice overex-
pressing GSK3β show reduced hippocampal degeneration,
indicating that tau partially contributes to the pathology
observed in mouse brain [39]. Finally, GSK3β inhibitors
decrease tau phosphorylation and amyloid deposition in6 International Journal of Alzheimer’s Disease
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Figure 3: Schematic representation of pre- and postsynaptic mechanisms involved in neuronal plasticity and the role of GSK3. In the
presynapse GSK3 activity decreases the expression of SynI reducing the release of glutamate while in postsynapses GSK3 transiently activates
NMDA receptors leading to endocytosis of AMPA receptors and reduces the levels of PSD93 protein, favoring LTD. In contrast, Wnt and
PI3K signaling pathways or pharmacological inhibition of GSK3 by LiCl supports the induction of LTP, facilitating learning and memory.
GSK3 inhibition is also involved in axon and dendritic widening in both pre- and postsynaptic sites. Serine/threonine phosphatases PP1
and PP2A can activate GSK3 regulating phosphor-GSK3 levels through its dephosphorylation. GSK3 is important in the modulation of
multiple signaling pathways including Notch pathway that plays an important role in diﬀerent developmental processes. In AD, amyloid-
β oligomers inhibit Wnt and insulin signaling pathways leading to activation of GSK3. In addition, GSK3 overactivation mediates τ
hyperphosphorylation and microtubule destabilization.
a double transgenic mouse model coexpressing human
mutant amyloid precursor protein (APP) and tau [137].
In brains of AD patients, GSK3β colocalizes with NFT
[138], and active GSK3β is present in neuronal cytoplasm
of neurons with tangle-like inclusions when abnormal tau
hyperphosphorylation begins [139]. In fact, polymorphisms
in GSK3 were recently reported to be risk factors for late-
onset AD [140, 141].
Evidence suggests that GSK3β regulates APP processing
[126, 142], leading to increased production of Aβ.N e u r o n a l
exposure to Aβ increases GSK3β activity through PI3K inhi-
bition [143], causing a positive feedback loop. Aβ peptide
can regulate GSK3 activity, acting as an insulin receptor
antagonist and preventing activation of PI3K and Akt. In
turn, the absence of activated Akt prevents the inhibitory
phosphorylation of GSK3, increasing its activity [144]. Aβ
seems to interfere with the Wnt canonical pathway as well,
leading to increased GSK3 activity [145]. Thus, deregulation
of GSK3 in AD might be due, in part, to alterations in insulin
and Wnt signaling. In the canonical Wnt signaling pathway,
t h eg e n ef o rL R P 6c o r e c e p t o rh a sb e e ni d e n t i ﬁ e da sar i s k
factorforlate-onsetADinApoE4-negativeindividuals[146].
Interestingly, it has been suggested that the Wnt pathway
mightbeinhibitedbyApoEprotein,whichlikelybindstothe
coreceptor LRP5/6 [147]. Moreover, the ApoE4, implicated
in sporadic AD [148], may activate GSK3 [46, 149].
Wnt dysregulation has also been implicated in AD.
For example, protein Dickkopf-1 negatively modulates the
canonical Wnt signaling pathway and thus activates GSK3.
DKK1 colocalizes with NFT and dystrophic neurites inInternational Journal of Alzheimer’s Disease 7
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Figure 4: Proposed model of GSK3 activation by amyloid-β protein in AD. Amyloid-β oligomers bind to the insulin receptor and inhibit
PI3K/Akt pathway, and Akt is unable to phosphorylate and inactivate GSK3. Aβ also induces the expression of DKK1, which internalizes
LRP6 receptor and inhibits Wnt signaling leading to GSK3 activation. Aβ can bind to Frizzled receptor (FzR) and inactivate Wnt signaling
as well. ApoE also inhibits this signaling pathway and activates GSK3. Tau hyperphosphorylation and NFT formation may result from GSK3
overactivation.
degenerating neurons of AD brains [150]. Moreover, using
Wnt and PI3K signaling inhibitors, cultured cortical neurons
have shown increased tau phosphorylation and morphologi-
cal changes mediated by GSK3β [151]. Taken together, this
evidence suggests an important role for GSK3 in AD and
supports the notion that GSK3 could be the link between
amyloid and tau pathology [46]( Figure 4).
6. Concluding Remarks
GSK3 has attracted a great deal of interest due to the
myriad of processes it controls. GSK3 is implicated in
many fundamental functions, ranging from bioenergetics to
developmentalandplasticityevents,particularlyinthebrain.
Altered GSK3 activity in the brain negatively inﬂuences
neuronal structure, which in turn may aﬀect maintenance
of neuronal circuits that support cognitive function. The
use of therapeutic drugs to control GSK3 activity has been
hamperedbythevarietyofsubstratestargetedbythisenzyme
and the long-term ramiﬁcations of its downstream signaling.
Future studies could focus on identifying spatiotemporal
expression patterns of speciﬁc GSK3 isoforms in the brain
with the goal of developing speciﬁc inhibitors for clinical use
in devastating neurological diseases, such as AD.
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